Virus and Autoantigen-Specific CD4+ T Cells Are Key Effectors in a SCID Mouse Model of EBV-Associated Post-Transplant Lymphoproliferative Disorders

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Linnerbauer, Stefanie ^a,b,c   Behrends, Uta ^a,b,c   Adhikary, Dinesh ^a,b   Witter, Klaus ^d   Bornkamm, Georg W ^b   Mautner, Josef ^a,b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c German Center for Infection Research   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN;

ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL CULTURE; DISEASE MODEL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; MOUSE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; SCID MOUSE; TRANSMISSION; VIROLOGY;

ANIMALS; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED C57BL; MICE, SCID; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84901648309     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004068     Document Type: Article

References (52)

1. Javier RT, Butel JS, (2008) The history of tumor virology. Cancer research 68: 7693-7706.
2. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM, (2011) Translating tumor antigens into cancer vaccines. Clinical and vaccine immunology: CVI 18: 23-34.
3. Rickinson AB, Kieff E (2007) Epstein-Barr Virus. In: Knipe DM, Howley, P.M., editor. Fields Virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 2575-2627.
4. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
5. Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A, (2011) Immunotherapy for EBV-associated malignancies. International journal of hematology 93: 281-293.
6. Long HM, Taylor GS, Rickinson AB, (2011) Immune defence against EBV and EBV-associated disease. Current opinion in immunology 23: 258-264.
7. Uhlin M, Okas M, Gertow J, Uzunel M, Brismar TB, et al. (2010) A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer immunology, immunotherapy: CII 59: 473-477.
8. Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, et al. (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115: 2960-2970.
9. Jones K, Nourse JP, Morrison L, Nguyen-Van D, Moss DJ, et al. (2010) Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 116: 2245-2252.
10. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, et al. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
11. McAulay KA, Haque T, Urquhart G, Bellamy C, Guiretti D, et al. (2009) Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. Journal of immunology 182: 3892-3901.
12. Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, et al. (1995) Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 4: 73-79.
13. Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J, (2008) Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. J Virol 82: 3903-3911.
14. Hislop AD, Taylor GS, Sauce D, Rickinson AB, (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
15. Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, et al. (2001) Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. Journal of virology 75: 8649-8659.
16. Long HM, Haigh TA, Gudgeon NH, Leen AM, Tsang CW, et al. (2005) CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. Journal of virology 79: 4896-4907.
17. Munz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, et al. (2000) Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 191: 1649-1660.
18. Long HM, Leese AM, Chagoury OL, Connerty SR, Quarcoopome J, et al. (2011) Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. Journal of immunology 187: 92-101.
19. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, et al. (2006) Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203: 995-1006.
20. Adhikary D, Behrends U, Boerschmann H, Pfunder A, Burdach S, et al. (2007) Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+ T Cell Preparations for Therapy. PLoS ONE 2: e583.
21. Long HM, Zuo J, Leese AM, Gudgeon NH, Jia H, et al. (2009) CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. Blood 114: 807-815.
22. Kieff E, Rickinson AB (2007) Epstein-Barr Virus and Its Replication. In: Knipe DM, Howley, P.M., editor. Field's virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 2603-2654.
23. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, (1988) Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335: 256-259.
24. Mosier DE, Baird SM, Kirven MB, Gulizia RJ, Wilson DB, et al. (1990) EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. Current topics in microbiology and immunology 166: 317-323.
25. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, et al. (1993) Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 114: 218-225 discussion 226.
26. Mosier DE, Picchio GR, Kirven MB, Garnier JL, Torbett BE, et al. (1992) EBV-induced human B cell lymphomas in hu-PBL-SCID mice. AIDS research and human retroviruses 8: 735-740.
27. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, et al. (1996) Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. The Journal of experimental medicine 183: 1215-1228.
28. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, et al. (1991) Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. The Journal of experimental medicine 173: 147-158.
29. Delecluse HJ, Feederle R, O'Sullivan B, Taniere P, (2007) Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol 60: 1358-1364.
30. Mautner J, Pich D, Nimmerjahn F, Milosevic S, Adhikary D, et al. (2004) Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol 34: 2500-2509.
31. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. The Journal of clinical investigation 115: 1616-1626.
32. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, et al. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
33. Coles RE, Boyle TJ, DiMaio JM, Berend KR, Via DF, et al. (1994) T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. Annals of surgical oncology 1: 405-410.
34. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, et al. (2005) Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. Journal of virology 79: 13993-14003.
35. Hong GK, Kumar P, Wang L, Damania B, Gulley ML, et al. (2005) Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. Journal of virology 79: 13984-13992.
36. Appay V, van Lier RA, Sallusto F, Roederer M, (2008) Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry Part A: the journal of the International Society for Analytical Cytology 73: 975-983.
37. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
38. Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, et al. (2007) Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 17: 203-210.
39. Rencher SD, Slobod KS, Smith FS, Hurwitz JL, (1994) Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice. Transplantation 58: 629-633.
40. Merlo A, Turrini R, Bobisse S, Zamarchi R, Alaggio R, et al. (2010) Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. Journal of immunology 184: 5895-5902.
41. Mauray S, Fuzzati-Armentero MT, Trouillet P, Ruegg M, Nicoloso G, et al. (2000) Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. European journal of immunology 30: 2065-2073.
42. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, et al. (2013) Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31: 39-48.
43. Gottschalk S, Heslop HE, Rooney CM, (2005) Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 46: 1-10.
44. Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, et al. (2010) Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116: 4700-4702.
45. Zhang B, Kracker S, Yasuda T, Casola S, Vanneman M, et al. (2012) Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148: 739-751.
46. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, et al. (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200: 1623-1633.
47. Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, et al. (2009) Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Molecular therapy: the journal of the American Society of Gene Therapy 17: 1616-1625.
48. Kempkes B, Pich D, Zeidler R, Sugden B, Hammerschmidt W, (1995) Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol 69: 231-238.
49. Feederle R, Kost M, Baumann M, Janz A, Drouet E, et al. (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19: 3080-3089.
50. Milosevic S, Behrends U, Adhikary D, Mautner J, (2006) Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach. J Virol 80: 10357-10364.
51. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, et al. (2003) Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 33: 1250-1259.
52. Turrini R, Merlo A, Dolcetti R, Zanovello P, Rosato A, (2011) Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. Cancer immunology, immunotherapy: CII 60: 1639-1645.